{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T15:44:54Z","timestamp":1762875894824},"reference-count":30,"publisher":"Georg Thieme Verlag KG","issue":"08","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thromb Haemost"],"published-print":{"date-parts":[[2017]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>The objective was to characterise apixaban pharmacodynamic (PD) activity in umbilical cord (UC), paediatric, and adult plasma. Plasma was obtained from blood samples from six UC donors, 70 paediatric (neonates [birth\u2013\u22641 month], infants [&gt;1\u2013\u22646 months], toddlers [&gt;6 months\u2013\u22642 years], young children [&gt;2\u2013\u22646 years], children [&gt;6\u2013\u226412 years], adolescents [&gt;12\u2013\u226418 years]), and six adult (19\u201345 years) subjects. Plasma spiked with apixaban 0 (baseline), 30, or 110 ng\/ml was analysed for anti-factor Xa activity, factor X levels, prothrombin time (PT), and modified PT (mPT). Apixaban had similar concentration-related effects on anti-factor Xa activity across groups (30 ng\/ml: 0.223\u20130.295 IU\/ml; 110 ng\/ml: 1.212\u20131.474 IU\/ml). Endogenous baseline factor X levels were 43%\u201368% lower in plasma from UC and subjects \u22646 months versus adults. Factor Xa inhibition (percentage change from baseline in apparent factor X levels) was similar for both apixaban concentrations across groups, except UC, neonate, and infant groups, which showed greater inhibition vs adults for apixaban 110 ng\/ml. Baseline PT and mPT were similar across groups. Apixaban had no effect on PT at the concentrations tested. Apixaban 110 ng\/ml prolonged mPT similarly across groups (44.4\u201353.2 s to 64.5\u201370.0 s); no prolongation was found with apixaban 30 ng\/ml. Apixaban demonstrated consistent concentration-related effects on other PD endpoints in plasma samples from all age groups, except factor Xa inhibition.<\/jats:p><jats:p>Supplementary Material to this article is available at www.thrombosis-online.com.<\/jats:p>","DOI":"10.1160\/th16-06-0423","type":"journal-article","created":{"date-parts":[[2017,5,24]],"date-time":"2017-05-24T08:59:30Z","timestamp":1495616370000},"page":"1518-1527","source":"Crossref","is-referenced-by-count":8,"title":["Apixaban pharmacodynamic activity in umbilical cord, paediatric, and adult plasma"],"prefix":"10.1160","volume":"117","author":[{"given":"Robert","family":"Yetman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Barrett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhaoqing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Adamczyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo","family":"Ramacciotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Frost","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2017,11,22]]},"reference":[{"key":"10.1160\/TH16-06-0423-1","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1182\/blood.V72.5.1651.1651","volume":"72","author":"Andrew","year":"1988","journal-title":"Blood"},{"key":"10.1160\/TH16-06-0423-2","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1182\/blood.V70.1.165.165","volume":"70","author":"Andrew","year":"1987","journal-title":"Blood"},{"key":"10.1160\/TH16-06-0423-3","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1182\/blood.V80.8.1998.1998","volume":"80","author":"Andrew","year":"1992","journal-title":"Blood"},{"key":"10.1160\/TH16-06-0423-4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2008.02939.x"},{"key":"10.1160\/TH16-06-0423-5","unstructured":"Bristol-Myers Squibb, Pfizer EEIG. Eliquis\u00ae (apixaban tablets) Summary of product characteristics. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002148\/WC500107728.pdf. Accessed February 25, 2016"},{"key":"10.1160\/TH16-06-0423-6","unstructured":"Bristol-Myers Squibb Company PI. Eliquis (apixaban) prescribing information. Available at: http:\/\/packageinserts.bms.com\/pi\/pi_eliquis.pdf. Accessed February 25, 2016"},{"key":"10.1160\/TH16-06-0423-7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2012.04369.x"},{"key":"10.1160\/TH16-06-0423-8","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12106"},{"key":"10.1160\/TH16-06-0423-9","doi-asserted-by":"publisher","DOI":"10.1160\/TH10-05-0328"},{"key":"10.1160\/TH16-06-0423-10","doi-asserted-by":"publisher","DOI":"10.1177\/1076029612441859"},{"key":"10.1160\/TH16-06-0423-11","doi-asserted-by":"publisher","DOI":"10.1160\/TH10-04-0247"},{"key":"10.1160\/TH16-06-0423-12","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-011-0591-8"},{"key":"10.1160\/TH16-06-0423-13","unstructured":"Byon W, Sweeney K, Frost C, Boyd R. Population pharmacokinetic analysis of apixaban in venous thromboembolism treatment patients. J Pharmacokinet Pharmacodynam 2014; 41: S65 (Abstract T-060)"},{"key":"10.1160\/TH16-06-0423-14","unstructured":"Kowalski K, Nielsen J, Roy A, et al. Apixaban exposure and anti-Xa activity in nonvalvular atrial fibrillation patients: an application of population PK\/PD analysis. J Pharmacokinet Pharmacodyn 2014; 41: S19 (Abstract M-027)"},{"key":"10.1160\/TH16-06-0423-15","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23619"},{"key":"10.1160\/TH16-06-0423-16","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2014.34"},{"key":"10.1160\/TH16-06-0423-17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810773"},{"key":"10.1160\/TH16-06-0423-18","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)62125-5"},{"key":"10.1160\/TH16-06-0423-19","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1160\/TH05-01-0047","volume":"95","author":"Monagle","year":"2006","journal-title":"Thromb Haemost"},{"key":"10.1160\/TH16-06-0423-20","doi-asserted-by":"publisher","DOI":"10.1097\/MBC.0000000000000033"},{"key":"10.1160\/TH16-06-0423-21","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1055\/s-0038-1648971","volume":"72","author":"Andrew","year":"1994","journal-title":"Thromb Haemost"},{"key":"10.1160\/TH16-06-0423-22","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1055\/s-0037-1613056","volume":"87","author":"Chan","year":"2002","journal-title":"Thromb Haemost"},{"key":"10.1160\/TH16-06-0423-23","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2008.07.009"},{"key":"10.1160\/TH16-06-0423-24","first-page":"570","volume":"80","author":"Massicotte","year":"1998","journal-title":"Thromb Haemost"},{"key":"10.1160\/TH16-06-0423-25","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.2.5652.281"},{"key":"10.1160\/TH16-06-0423-26","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2004.07.003"},{"key":"10.1160\/TH16-06-0423-27","doi-asserted-by":"publisher","DOI":"10.1186\/1477-9560-12-24"},{"key":"10.1160\/TH16-06-0423-28","first-page":"179","volume":"6","author":"Frost","year":"2014","journal-title":"Clin Pharmacol"},{"key":"10.1160\/TH16-06-0423-29","unstructured":"Clinicaltrials.gov. Study to evaluate a single dose of apixaban in pediatric subjects at risk for a thrombotic disorder. Available at: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01707394. Accessed March 23, 2016"},{"key":"10.1160\/TH16-06-0423-30","unstructured":"Clinicaltrials.gov. Apixaban for the acute treatment of venous thromboembolism in children. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02464969. Accessed March 23, 2016"}],"container-title":["Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1160\/TH16-06-0423.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,8]],"date-time":"2020-10-08T10:36:40Z","timestamp":1602153400000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1160\/TH16-06-0423"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":30,"journal-issue":{"issue":"08","published-online":{"date-parts":[[2017,11,22]]},"published-print":{"date-parts":[[2017,8]]}},"URL":"https:\/\/doi.org\/10.1160\/th16-06-0423","relation":{},"ISSN":["0340-6245","2567-689X"],"issn-type":[{"value":"0340-6245","type":"print"},{"value":"2567-689X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]}}}